AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03860844 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daunorubicin (nonliposomal)
Description: Pharmaceutical form: Solution for injection Route of administration: Intravenous infusion
Study NCT03860844 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idarubicin
Description: Pharmaceutical form: Solution for injection Route of administration: Intravenous
Study NCT01822366 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Trauma-focused Cognitive Behavioral Therapy
Study NCT03860844 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Filgrastim or equivalent
Description: Pharmaceutical form: Solution for injection Route of administration: Intravenous
Study NCT03860844 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitoxantrone
Description: Pharmaceutical form: Solution for injection Route of administration: Intravenous
Study NCT03860844 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Pharmaceutical form: Solution for injection Route of administration: Intravenous
Study NCT03860844 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Pharmaceutical form: Solution for injection Route of administration: Intravenous
Study NCT03860844 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegaspargase (PEG) Asparaginase
Description: Pharmaceutical form: Solution for injection Route of administration: Intravenous infusion
Study NCT03860844 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Pharmaceutical form: Solution for injection Route of administration: Intravenous
Study NCT03860844 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Pharmaceutical form: Solution for injection Route of administration: Intravenous infusion
Study NCT03860844 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Pharmaceutical form: Solution for injection Route of administration: Intravenous infusion
Study NCT03860844 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L - Asparginase
Description: Pharmaceutical form: Solution for injection Route of administration: Intramuscular
Study NCT03860844 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxyurea
Description: Pharmaceutical form: Solution for injection Route of administration: PO
Study NCT03860844 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L - Asparaginase (Erwinase)
Description: Pharmaceutical form: Solution for injection Route of administration: Intramuscular
Study NCT02505269 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brentuximab Vedotin
Study NCT02505269 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adriamycin
Study NCT02505269 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dacarbazine
Study NCT03028532 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clomid
Description: Participants will self-administer Clomid (50mg oral tablet) once daily for 30 consecutive days
Study NCT04494984 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: INM005
Description: The IMP dose to be studied will be 4 mg of protein/kg of subject's weight. The IMP will be added to the 100 mL infusion bag of saline solution. Doses will be administered as an infusion at 2.0 mL/min over 50 min with an interval of 48 h between doses.
Study NCT04494984 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo substance will be added to the 100 mL infusion bag of saline solution. Doses will be administered as an infusion at 2.0 mL/min over 50 min with an interval of 48 h between doses.
Study NCT03465137 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Coordinated Anxiety Learning and Management (CALM)
Description: Exposure-focused cognitive behavioral therapy
Study NCT01480791 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aliskiren vs. hydrochlorothiazide
Description: Aliskiren will be used at increasing doses from 150 to 300 mg per day for 6-12 months.
Study NCT01480791 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide
Description: Hydrochlorothiazide will be used at increasing doses from 12.5 to 25 mg per day for 6-12 months.
Study NCT01480791 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydrochlorothiazide
Description: Hydrochlorothiazide will be used at increasing doses from 12.5 to 25 mg per day for 6-12 months.
Study NCT00726310 — intervention group
Intervention type: DEVICE
Intervention: SpineLink® , SpineLink® II
Description: Spine plate system for lumbar spinal fusions
Study NCT03687827 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin degludec
Description: Participants will receive insulin degludec U100 subcutaneous (s.c.) injection once daily for 36 weeks. Doses will be adjusted according to the fasting self-measured plasma glucose (SMPG) values. Participants earlier treated with one or more allowed oral antidiabetic drug(s) (OAD(s)), should continue their pre-trial OAD(s) treatment throughout the trial.
Study NCT03687827 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin glargine
Description: Participants will receive insulin glargine U100 s.c. injection once daily for 36 weeks. Doses will be adjusted according to the fasting SMPG values. Participants earlier treated with one or more allowed OAD(s), should continue their pre-trial OAD(s) treatment throughout the trial.
Study NCT04539665 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Extended mesenteric resection.
Description: Patients will undergo an ileocolic resection involving high ligation of the ileocolic pedicle, complete mobilization of the mesentery off of the retroperitoneum, and resection of the entire mesentery related to the specimen.
Study NCT02949687 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ileal interposition with sleeve and sympathectomy
Description: laparoscopic ileal interposition with sleeve and sympathectomy
Study NCT02866773 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PA1: Education sessions, Reminders, Whataps group
Description: The intervention includes three components:~* Physical activity knowledge enhancement session: one core session and one booster session on increasing physical activity and reducing sedentary behavior~* Physical activity Anti-inertia Reminder: souvenirs and electronic healthy messages are sent to participants in this group to promote the awareness of performing regular exercise~* Physical activity ambassadors' electronic communication group: the community leaders and ambassadors' formed an electronic communication group to share their experience on performing regular physical activity and program implementation.
Study NCT02866773 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PA2: Education sessions, Reminders
Description: The intervention includes two components:~* Physical activity knowledge enhancement session: one core session and one booster session on increasing physical activity and reducing sedentary behavior~* Physical activity Anti-inertia Reminder: souvenirs and electronic healthy messages are sent to participants in this group to promote the awareness of performing regular exercise
Study NCT02866773 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: PA2: Education sessions, Reminders
Description: The intervention includes two components:~* Physical activity knowledge enhancement session: one core session and one booster session on increasing physical activity and reducing sedentary behavior~* Physical activity Anti-inertia Reminder: souvenirs and electronic healthy messages are sent to participants in this group to promote the awareness of performing regular exercise
Study NCT02866773 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PA3: Education sessions, Whataps group
Description: The intervention includes two components:~* Physical activity knowledge enhancement session: one core session and one booster session on increasing physical activity and reducing sedentary behavior.~* Physical activity ambassadors' electronic communication group: the community leaders and ambassadors' formed an electronic communication group to share their experience on performing regular physical activity and program implementation.
Study NCT02866773 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: PA3: Education sessions, Whataps group
Description: The intervention includes two components:~* Physical activity knowledge enhancement session: one core session and one booster session on increasing physical activity and reducing sedentary behavior.~* Physical activity ambassadors' electronic communication group: the community leaders and ambassadors' formed an electronic communication group to share their experience on performing regular physical activity and program implementation.
Study NCT02866773 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PA4: Education sessions
Description: The intervention includes one component only:~- Physical activity knowledge enhancement session: one core session and one booster session on increasing physical activity and reducing sedentary behavior
Study NCT02866773 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: PA4: Education sessions
Description: The intervention includes one component only:~- Physical activity knowledge enhancement session: one core session and one booster session on increasing physical activity and reducing sedentary behavior
Study NCT02866773 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HD1: Education sessions, Reminders, Whataps group
Description: The intervention includes two components:~- Healthy diet knowledge enhancement session: one core session and one booster session on increasing reducing sugary intake.~Healthy diet Anti-inertia Reminder: souvenirs and electronic healthy messages are sent to participants in this group to promote the awareness of reducing sugary intake.~- Healthy diet ambassadors' electronic communication group: the community leaders and ambassadors' formed an electronic communication group to share their experience on reducing sugary intake and program implementation.
Study NCT02866773 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HD2: Education sessions, Reminders
Description: The intervention includes two components:~* Healthy diet knowledge enhancement session: one core session and one booster session on increasing reducing sugary intake.~* Healthy diet Anti-inertia Reminder: souvenirs and electronic healthy messages are sent to participants in this group to promote the awareness of reducing sugary intake.
Study NCT02866773 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: HD2: Education sessions, Reminders
Description: The intervention includes two components:~* Healthy diet knowledge enhancement session: one core session and one booster session on increasing reducing sugary intake.~* Healthy diet Anti-inertia Reminder: souvenirs and electronic healthy messages are sent to participants in this group to promote the awareness of reducing sugary intake.
Study NCT02866773 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HD3:Education sessions, Whataps group
Description: The intervention includes two components:~* Healthy diet knowledge enhancement session: one core session and one booster session on increasing reducing sugary intake.~* Healthy diet ambassadors' electronic communication group: the community leaders and ambassadors' formed an electronic communication group to share their experience on reducing sugary intake and program implementation.
Study NCT02866773 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: HD3:Education sessions, Whataps group
Description: The intervention includes two components:~* Healthy diet knowledge enhancement session: one core session and one booster session on increasing reducing sugary intake.~* Healthy diet ambassadors' electronic communication group: the community leaders and ambassadors' formed an electronic communication group to share their experience on reducing sugary intake and program implementation.
Study NCT02866773 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HD4: Education sessions
Description: The intervention includes one component only:~- Healthy diet knowledge enhancement session: one core session and one booster session on increasing reducing sugary intake.
Study NCT05979558 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ropivacaine with dexmedetomidine
Description: this group received with ropivacaine with dexmedetomidine
Study NCT05979558 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ropivacaine with placebo
Description: this group received with ropivacaine with normal saline
Study NCT00946699 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MEDI-551
Description: 0.1 mg/kg
Study NCT00946699 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 0.3 mg/kg
Study NCT00946699 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MEDI-551
Description: 1.0 mg/kg
Study NCT00946699 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MEDI-551
Description: 3.0 mg/kg
Study NCT00946699 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MEDI-551
Description: 10.0 mg/kg
Study NCT00946699 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT02725710 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gabapentin
Description: 600mg Gabapentin administered orally 1-2 hours prior to procedure
Study NCT02725710 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Identical looking pill to the 600mg Gabapentin pill administered orally 1-2 hours prior to procedure
Study NCT02866773 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: HD4: Education sessions
Description: The intervention includes one component only:~- Healthy diet knowledge enhancement session: one core session and one booster session on increasing reducing sugary intake.
Study NCT04429074 — intervention group
Intervention type: PROCEDURE
Intervention: Minimally invasive distal pancreatectomy
Description: Minimally invasive distal pancreatectomy
Study NCT03456050 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: FRC exercise
Description: The program will consist of hip joint controlled articular rotations (CARs) in standing position for 3 - 5 repetitions. Then, the participant will sit on the floor in what is called 90/90 position which is sitting in hip and flexion in 90 degrees for both the lead (front) and trail (side) leg. The participant will perform a Progressive and regressive angular isometric loadings (PAILs and RAILs) for the trail leg to increase the range of internal rotation, the contraction will be performed three times and the holding of the position will be for two minutes. After expanding the range, the participant will perform Progressive and regressive angular loadings (PALs and RALs) isometric contractions in form of a passive range hold for internal rotation and abduction, for 3 - 5 times.
Study NCT02283372 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nab-Paclitaxel
Study NCT02283372 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Study NCT02283372 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity modulated radiation
Study NCT02497053 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pemetrexed/platinum chemotherapy
Description: Four cycles of pemetrexed/platinum chemotherapy
Study NCT02497053 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pemetrexed/platinum chemotherapy
Description: Six cycles of pemetrexed/platinum chemotherapy
Study NCT03793790 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Conditioning with partial reinforcement
Description: Conditioning with partial reinforcement (PRF) provides an uncertain pairing of unconditioned high pain stimuli and conditioned stimuli (i.e., on-screen messages signaling the activation of a mock medical device). During PRF only 70 percent of unconditioned stimuli are paired to conditioned stimuli. Pain of only moderate intensity is used for control stimuli that are paired to the deactivation of the mock device and are also used in the 30 percent of unreinforced trials.
Study NCT03456050 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Conventional Exercise
Description: The conventional training program in this study will be the routine training for increasing the hip rotation. By screening the scientific literature, the conventional training found to consists of static stretching and strengthening using body weight and/or a band and the time of holding a stretch is about 30 seconds. For that the flexibility exercise will consist of progressive stretching from a prone position (leg fall in a stretch), the participant will perform 3 - 5 repetitions with 30 seconds hold or as tolerated. The strengthening exercise consists of hip abduction (hip opening) using a band or ankle weight from side lying for 10 - 12 repetitions 3 times.
Study NCT01802931 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GSK239512
Description: H3 receptor antagonist, potential victim of drug-drug interaction
Study NCT03793790 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Conditioning with continuous reinforcement
Description: During conditioning with continuous reinforcement (CRF) unconditioned high pain stimuli are paired to conditioned stimuli (i.e., on-screen messages signaling the activation of a mock medical device) in 100 percent of conditioning trials. Pain of only moderate intensity is used for control stimuli that are paired to the deactivation of the mock device.
Study NCT03793790 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Counterconditioning
Description: During counterconditioning, the previously conditioned nocebo effects on pain are attenuated by pairing the same conditioned stimuli (i.e., on-screen messages signaling the activation of a mock medical device) to thermal pain stimuli of low intensity.
Study NCT03793790 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Extinction
Description: During extinction, the previously conditioned nocebo effects on pain are attenuated by pairing the same conditioned stimuli (i.e., on-screen messages signaling the activation of a mock medical device) only to control stimuli of moderate intensity (previously paired to the deactivation of the mock device).
Study NCT03793790 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Sham Conditioning
Description: In the sham group, participants receive different instructions (namely, that the activation of the device is not expected to affect their pain sensitivity). Additionally, during sham conditioning unconditioned stimuli are not consistently paired to conditioned stimuli, thereby preventing the formation of an association between high pain stimuli and the activation of the mock medical device. In the attenuation phase participants undergo an extinction procedure.
Study NCT01802931 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ketoconazole
Description: CYP3A4 inhibitor, potential perpetrator of drug-drug interaction
Study NCT02654730 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dihydroartemisinin-piperaquine (DHAP) administered to G6PD deficient
Description: G6PD deficient participants will be treated with dihydroartemisinin-piperaquine (Eurartesim®; Sigma Tau) administered as 3 tablets (40mg PPQ, 320mg DHA) in a once daily regimen for three days
Study NCT02654730 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin-piperaquine (DHAP) + 0.25 mg/kg primaquine administered to G6PD deficient
Description: G6PD deficient participants will be treated with dihydroartemisinin-piperaquine (Eurartesim®; Sigma Tau) administered as 3 tablets (40mg PPQ, 320mg DHA) in a once daily regimen for three days in combination with a single dose of 0.25mg/kg of primaquine on the first day of DHAP treatment.
Study NCT02654730 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin-piperaquine (DHAP) + 0.4 mg/kg primaquine administered to G6PD deficient
Description: G6PD deficient participants will be treated with dihydroartemisinin-piperaquine (Eurartesim®; Sigma Tau) administered as 3 tablets (40mg PPQ, 320mg DHA) in a once daily regimen for three days in combination with a single dose of 0.4mg/kg of primaquine on the first day of DHAP treatment.
Study NCT02654730 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dihydroartemisinin-piperaquine (DHAP) + 0.25 mg/kg primaquine administered to G6PD normal
Description: G6PD normal participants will be treated with dihydroartemisinin-piperaquine (Eurartesim®; Sigma Tau) administered as 3 tablets (40mg PPQ, 320mg DHA) in a once daily regimen for three days in combination with a single dose of 0.25mg/kg of primaquine on the first day of DHAP treatment.
Study NCT02654730 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dihydroartemisinin-piperaquine (DHAP) + 0.4 mg/kg primaquine administered to G6PD normal
Description: G6PD normal participants will be treated with dihydroartemisinin-piperaquine (Eurartesim®; Sigma Tau) administered as 3 tablets (40mg PPQ, 320mg DHA) in a once daily regimen for three days in combination with a single dose of 0.4mg/kg of primaquine on the first day of DHAP treatment.
Study NCT00108615 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Study NCT00108615 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Study NCT00108615 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Study NCT00108615 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pioglitazone
Study NCT00108615 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: CT scans
Description: To measure changes in adipose tissue volumes